Back to Search
Start Over
Prophylactic intravitreal injection of aflibercept for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy: A randomized controlled trial.
- Source :
-
Frontiers in public health [Front Public Health] 2023 Jan 11; Vol. 10, pp. 1067670. Date of Electronic Publication: 2023 Jan 11 (Print Publication: 2022). - Publication Year :
- 2023
-
Abstract
- Introduction: The aim of this study was to assess the effects of preoperative intravitreal aflibercept (IVA) injection on the incidence of postoperative vitreous hemorrhage (VH) after vitrectomy for proliferative diabetic retinopathy (PDR).<br />Methods: This study involved a prospective, randomized clinical trial. One hundred twenty-eight eyes of 128 patients of PDR who underwent pars plana vitrectomy (PPV) were enrolled. Sixty-four eyes were assigned randomly to either the IVA group (IVA injection 1 to 5 days before PPV) or the control group (no IVA injection). The primary outcome was the incidence of VH at 1 month after PPV. Secondary outcome measures were best-corrected visual acuity (BCVA) changes from baseline to at 1 week, 1 month, 2 months, and 3 months after surgery.<br />Results: The VH incidences in the IVA group and the control group were 14.8 and 39.3% at week 1, 8.6 and 31.7% at month 1, 11.7 and 30.5% at month 2, and 8.6 and 30.5% at month 3, respectively. Intergroup differences showed a significantly decreased VH rate in the IVA group compared with that in the control group at week 1, month 1, and month 3 ( p = 0.021, 0.006, and 0.047, respectively). Compared to the baseline, neither the mean BCVA nor the BCVA change in the Logarithm of the Minimum Angle of Resolution (logMAR) scale did differ significantly between the two groups at each visit point. There are a greater number of eyes with BCVA improvement of more than 2 logMAR in the IVA group than in the control group at week 1 (8 vs. 2, p = 0.048).<br />Conclusions: This study found that the adjunctive use of preoperative IVA reduces early and late postoperative VH in vitrectomy for PDR.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2023 Qu, Chen, Liu, Wang, Li, Zhou, Yao and Li.)
- Subjects :
- Humans
Bevacizumab therapeutic use
Intravitreal Injections
Angiogenesis Inhibitors therapeutic use
Antibodies, Monoclonal, Humanized therapeutic use
Vascular Endothelial Growth Factor A
Prospective Studies
Vitreous Hemorrhage etiology
Vitreous Hemorrhage prevention & control
Diabetic Retinopathy
Diabetes Mellitus
Subjects
Details
- Language :
- English
- ISSN :
- 2296-2565
- Volume :
- 10
- Database :
- MEDLINE
- Journal :
- Frontiers in public health
- Publication Type :
- Academic Journal
- Accession number :
- 36711366
- Full Text :
- https://doi.org/10.3389/fpubh.2022.1067670